| NDC包装代码 | 产品NDC | 产品类型 | 商品名 | 通用名 | 剂型 | 给药途径 | 上市日期 | 结束日期 | 市场类别 | 申请号 | 标签持有者 | 活性成分 | 规格 | 包装描述 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 42385-920-48 | 42385-920 | HUMAN PRESCRIPTION DRUG | Atazanavir | Atazanavir | CAPSULE | ORAL | 20210430 | N/A | ANDA | ANDA212579 | Laurus Labs Limited | ATAZANAVIR SULFATE | 150 mg/1 | 10 BLISTER PACK in 1 CARTON (42385-920-48) / 6 CAPSULE in 1 BLISTER PACK (42385-920-06) |
| 42385-920-60 | 42385-920 | HUMAN PRESCRIPTION DRUG | Atazanavir | Atazanavir | CAPSULE | ORAL | 20210430 | N/A | ANDA | ANDA212579 | Laurus Labs Limited | ATAZANAVIR SULFATE | 150 mg/1 | 60 CAPSULE in 1 BOTTLE (42385-920-60) |
| 42385-921-48 | 42385-921 | HUMAN PRESCRIPTION DRUG | Atazanavir | Atazanavir | CAPSULE | ORAL | 20210430 | N/A | ANDA | ANDA212579 | Laurus Labs Limited | ATAZANAVIR SULFATE | 200 mg/1 | 10 BLISTER PACK in 1 CARTON (42385-921-48) / 6 CAPSULE in 1 BLISTER PACK (42385-921-06) |
| 42385-921-60 | 42385-921 | HUMAN PRESCRIPTION DRUG | Atazanavir | Atazanavir | CAPSULE | ORAL | 20210430 | N/A | ANDA | ANDA212579 | Laurus Labs Limited | ATAZANAVIR SULFATE | 200 mg/1 | 60 CAPSULE in 1 BOTTLE (42385-921-60) |
| 42385-922-30 | 42385-922 | HUMAN PRESCRIPTION DRUG | Atazanavir | Atazanavir | CAPSULE | ORAL | 20210430 | N/A | ANDA | ANDA212579 | Laurus Labs Limited | ATAZANAVIR SULFATE | 300 mg/1 | 30 CAPSULE in 1 BOTTLE (42385-922-30) |
| 42385-922-37 | 42385-922 | HUMAN PRESCRIPTION DRUG | Atazanavir | Atazanavir | CAPSULE | ORAL | 20210430 | N/A | ANDA | ANDA212579 | Laurus Labs Limited | ATAZANAVIR SULFATE | 300 mg/1 | 5 BLISTER PACK in 1 CARTON (42385-922-37) / 6 CAPSULE in 1 BLISTER PACK (42385-922-06) |